EGFR and non-small cell lung carcinoma: We recently published a randomized study in EGFR-mutated NSCLC warranting palliative therapy comparing pemetrexed-carboplatin to gefitinib in first-line setting (Clinical Trials Registry-India: CTRI/2015/08/006113) [6].